A recent L.E.K. Consulting report found that about 40% of meds approved between 2004 and 2016 underperformed Wall Street’s prelaunch sales forecasts by over 20% in their first three years on market.
To follow is a list of 10 drug launches from the past five years that suffered some of the most significant failures. The companies range from big pharma to biotech startups in various therapeutic areas.
Click here to read the entire article.